Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
LENTIVIRAL VECTOR SUITABLE FOR GENE THERAPY OF REFRACTORY ANGIOGENIC EYE DISEASES
Document Type and Number:
WIPO Patent Application WO/2023/093405
Kind Code:
A1
Abstract:
Provided is a lentiviral vector suitable for gene therapy of refractory angiogenic eye diseases. A packaging plasmid comprises pMD.2G for expressing envelope protein, pRSV-REV for expressing REV protein, pMDlg/pRRE or pMDlg/pRRE-IN mut for expressing Gag-Pol, and a vector plasmid for expressing a VEGFA antibody gene. The vector plasmid is constructed by replacing an eGFP gene in a plasmid pCCL-PGK-eGFP with an anti-VEGFA gene. The anti-VEGFA gene is obtained by respectively adding an Fc fragment constant region CH3 of human IgG to a heavy chain variable region and a light chain variable region of Ranibizumab and carrying out codon optimization on the gene.

Inventors:
LING SIKAI (CN)
WANG XIAOYUAN (CN)
Application Number:
PCT/CN2022/126891
Publication Date:
June 01, 2023
Filing Date:
October 24, 2022
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHANGHAI BDGENE TECH CO LTD (CN)
International Classes:
C12N15/867; A61K39/395; A61P3/10; A61P9/10; A61P27/02; C07K16/22; C12N9/12; C12N15/13; C12N15/54
Foreign References:
CN114181972A2022-03-15
CN101951925A2011-01-19
CN102083462A2011-06-01
CN110452297A2019-11-15
Other References:
YANG, ZHI ET AL.: "The Study of Calcium Phosphate Transfection Method for Third Generation Self-Inactivating Lentivirus Production", JOURNAL OF ZHEJIANG SCI-TECH UNIVERSITY, vol. 27, no. 2, 31 March 2010 (2010-03-31)
MENG, FANRONG ET AL.: "Advances of Lentiviral Vectors", CHINESE JOURNAL OF LUNG CANCER, vol. 17, no. 12, 20 December 2014 (2014-12-20), XP055642355, DOI: 10.3779/j.issn.1009-3419.2014.12.09
DATABASE PROTEIN ANONYMOUS : "integrase, partial [Human immunodeficiency virus 1]", XP093068091, retrieved from NCBI
Attorney, Agent or Firm:
DUAN&DUAN LAW FIRM (CN)
Download PDF: